Stockscreener 앱 받기
0.7267
0.59%
-0.0043
시간 외 거래:
.73
0.0033
+0.45%
전일 마감가:
$0.731
열려 있는:
$0.73
하루 거래량:
403.00K
Relative Volume:
0.17
시가총액:
$11.79M
수익:
$2.05M
순이익/손실:
$-23.15M
주가수익비율:
-0.1096
EPS:
-6.6319
순현금흐름:
$-16.93M
1주 성능:
-5.01%
1개월 성능:
-5.75%
6개월 성능:
-75.11%
1년 성능:
-66.20%
1일 변동 폭
$0.7202
$0.73
1주일 범위
$0.7159
$0.79
52주 변동 폭
$0.6358
$6.8908
iBio Inc Stock (IBIO) Company Profile
명칭
iBio Inc
전화
302-355-0650
주소
600 Madison Avenue, Suite 1601, New York, NY
IBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.7267 | 12.41M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-28 | 개시 | Chardan Capital Markets | Buy |
| 2021-11-29 | 개시 | JMP Securities | Mkt Outperform |
| 2021-01-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 개시 | Alliance Global Partners | Buy |
iBio Inc 주식(IBIO)의 최신 뉴스
Is iBio Inc. a good long term investmentFree Smart Trading Workshop - jammulinksnews.com
What analysts say about iBio Inc. stockFree Expert Stock Watchlist - Autocar Professional
What drives iBio Inc. stock priceBreakthrough financial growth - Autocar Professional
how ibio stock performs during market volatilityFree Short-Term Stock Picks - Newser
iBio Inc. Stock Analysis and ForecastConsistent double returns - jammulinksnews.com
what makes ibio inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
What institutions are buying iBio Inc. stock nowFree Access to Investment Community - Newser
Why iBio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
What makes iBio Inc. stock price move sharplyChart Based Entries - Newser
IBIO’s Market Whiplash: -61.36% YTD Decline, -20.36% Plunge in 30 Days - investchronicle.com
How iBio Inc. stock performs during market volatilityFree Access to Investors Club - Newser
iBio (NYSEMKT:IBIO) Stock Price Down 0% – What’s Next? - Defense World
iBio stock soars after amylin receptor antibody shows promising results - Investing.com
iBio Advances Obesity Care with Antibody Therapies - TipRanks
iBio (IBIO) Reports Promising Preclinical Results in Obesity Stu - GuruFocus
US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of EarningsBlackBerry (NYSE:BB), Carnival (NYSE:CCL) - Benzinga
iBio's Next-Gen Obesity Therapies: A Strategic Pipeline with Transformative Potential - AInvest
iBio Extends Promissory Note Maturity to 2026 - TipRanks
Ibio nominates IBIO-610 as obesity development candidate - BioWorld MedTech
iBio initiates primate study for obesity antibody candidate IBIO-610 By Investing.com - Investing.com South Africa
iBio (IBIO) Begins Preclinical Study of New Antibody Candidate | - GuruFocus
iBio initiates primate study for obesity antibody candidate IBIO-610 - Investing.com
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | IBIO Stock News - GuruFocus
iBio initiates non-human primate study of IBIO-610 - TipRanks
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - The Manila Times
Breakthrough Obesity Drug Shows 77% Fat Reduction When Combined With GLP-1 Treatments - Stock Titan
iBio (IBIO) Plans to Offer 11.25 Million Shares of Common Stock - GuruFocus
Sector Update: Health Care - MarketScreener
IBio Files Prospectus for Resale of About 11.3 Million Shares - marketscreener.com
Plant-Based Vaccines Market Future Business Opportunities 2025-2032 | Medicago, Inc., IBIO, Icon Genetics GmbH - newstrail.com
iBio: University of Limerick programme to ‘shape the next generation’ of pharmaceutical manufacturing experts - University of Limerick
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Plant-Based Vaccines Market Detailed In New Research Report - openPR.com
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World
Chardan Capital Has Bearish Outlook for iBio FY2025 Earnings - Defense World
Would I Consider iBio Inc (NASDAQ: IBIO) Stock Any Time In The Future? - Stocksregister
Balance Sheet Dive: iBio Inc (IBIO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO S - GuruFocus
iBio’s (IBIO) Buy Rating Reaffirmed at Chardan Capital - Defense World
iBio (NYSEMKT:IBIO) Shares Down 1.9% – Time to Sell? - Defense World
IBIOIbio Latest Stock News & Market Updates - Stock Titan
iBio announces new preclinical data for Activin E antibody - TipRanks
iBio Inc (IBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):